NCT07043608 - Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2029

Conditions

Clear Cell Renal Cell Cancer (ccRCC)Clear Cell Renal CarcinomaClear Cell Renal Cell Carcinoma MetastaticClear Cell Renal CancerBone Metastases of a Malignant TumorClear Cell Renal Cell CarcinomaBone, Metastatic CancerMetastatic CancerMetastatic Renal Cell CarcinomaMetastases to Bone

Interventions

DRUG

Zanzalintinib

Given orally (PO)

DRUG

Investigator Choice of Bone Strengthening Agents (BSA)

One BSA will be chosen, at the discretion of the investigator and given intravenously (IV)

RADIATION

Non-Investigational Radiation Therapy (RT)

Non-investigational RT is permitted for symptomatic bone metastases.

PROCEDURE

Bone Scan

Undergo Bone Scan

PROCEDURE

Computerized tomography (CT) Scan

Undergo Imaging

Trial Locations (1)

94143

University of California, San Francisco, San Francisco